Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunome Inc (NQ: IMNM )

13.21 -0.10 (-0.75%)
Streaming Delayed Price Updated: 12:43 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 131,823
Open 13.52
Bid (Size) 13.17 (2)
Ask (Size) 13.23 (4)
Prev. Close 13.31
Today's Range 12.96 - 13.61
52wk Range 6.130 - 30.96
Shares Outstanding 59,968,868
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immunome Appoints Phil Tsai as Chief Technical Officer
From Immunome, Inc.
Via Business Wire
Evaluating Immunome: Insights From 4 Financial Analysts
Via Benzinga

Performance

YTD
+19.98%
+19.98%
1 Month
+6.19%
+6.19%
3 Month
-13.55%
-13.55%
6 Month
-15.59%
-15.59%
1 Year
+81.71%
+81.71%

More News

Read More
Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Immunome Announces Completion of Purchase of Assets from Atreca
From Immunome, Inc.
Via Business Wire
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
From Immunome, Inc.
Via Business Wire
IMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
Immunome to Present at 2024 Bank of America Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Appoints Kinney Horn as Chief Business Officer
From Immunome, Inc.
Via Business Wire
Immunome Appoints Sandra M. Swain to Board of Directors
From Immunome
Via Business Wire
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
From Immunome, Inc.
Via Business Wire
IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
From Immunome, Inc.
Via Business Wire
Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday?
Via Benzinga
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
From Immunome, Inc.
Via Business Wire
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
From Ayala Pharmaceuticals
Via GlobeNewswire
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Immunome to Participate in the Leerink Partners Global Biopharma Conference
From Immunome, Inc.
Via Business Wire
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
From Immunome, Inc.
Via Business Wire
Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue?
Via Benzinga
How I Swing Trade Via Strength With Recent Examples
Via Talk Markets
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
From Immunome, Inc.
Via Business Wire
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Immunome, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.